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Multiple Myeloma 
Definition 
Multiple myeloma is a neoplastic plasma-cell 
disorder that is characterized by clonal 
proliferation of malignant plasma cells in the 
bone marrow microenvironment, monoclonal 
protein in the blood or urine, and associated 
organ dysfunction. 
http://www.nejm.org/doi/pdf/10.1056/NEJMra1011442 
Epidemiology 
• It accounts for approximately 1% of neoplastic 
diseases and 13% of hematologic cancers. In 
Western countries, the annual age adjusted 
incidence is 5.6 cases per 100,000 persons. 
• The median age at diagnosis is approximately 
70 years; 37% of patients are younger than 65 
years, 26% are between the ages of 65 and 74 
years, and 37% are 75 years of age or older. 
• In patients presenting at an age under 60 
years, 10-year survival is approximately 30% 
Age-adjusted Incidence per 100,000 
Male Female 
White 6.2 4.1 
Black 11.8 10.0 
Normal Ig structure 
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Different secreting patterns  

A crystal of Bence Jones protein 
A crystal of Bence Jones protein created for X-ray crystallography, which can 
reveal detailed, three-dimensional protein structures The proteins are 
immunoglobulin light chains (paraproteins) and are produced by neoplastic 
plasma cells. They can be kappa (most of the time) or lambda. 
http://en.wikipedia.org/wiki/File:Bence_Jones_Protein_MLE1.jpg 
Henry Bence-Jones (1813-73). 
British Physician (St George’s 
Hospital) 
 
Patients & friends included Charles 
Darwin, Florence Nightingale, 
Thomas Huxley, Michael Faraday 
 
Thomas McBean’s urine was boiled. 
A protein precipitated at 60o and re-
dissolved on boiling 
World Health Organization 
 Classification  
• Monoclonal gammopathy of undetermined 
significance (MGUS) 
• Plasma cell myeloma (multiple myeloma) 
variants: 
• Indolent myeloma 
• Smoldering myeloma 
• Osteosclerotic myeloma (POEMS syndrome) 
• Plasma cell leukemia 
• Non-secretory myeloma 
Monoclonal gammopathy of 
undetermined significance 
• MGUS is defined as having serum M-protein 
< 3 g/dL, clonal plasma cell population in 
bone marrow < 10%, and absence of end-
organ damage (CRAB criteria of multiple 
myeloma) and has an average multiple 
myeloma progression risk of 1% per year. 
Natural development of myeloma 
Lymph Nodes 

Pathogenesis  
Multiple myeloma is a malignancy of plasma B cells 
caused by alterations to genetic material following B cell 
activation in the germinal centres of secondary lymphoid 
organs.  
Myeloma plasma B cells also express CXCR4 
receptors for SDF-1 α, a chemokine that regulates homing 
to the bone marrow where bone disease develops. 
Pathogenesis  
•B cells are primed by B cell 
receptor recognition of antigens 
presented by follicular dendritic 
cells in the germinal centres of 
secondary lymphoid organs. 
•CD4+ helper T cell interaction 
activates B cells to differentiate into 
plasma cells and also induces 
isotype switching and affinity 
maturation. During this process 
abnormal DNA recombination 
events translocate heavy and light 
immunoglobulin genes to other 
chromosomes and generate a 
malignant phenotype.  
•The myeloma plasma B cells 
continue to produce 
immunoglobulins resulting in a 
gammopathy and ultimately home 
to the bone marrow where bone 
disease develops. 
Pathogenesis  
•Bone destruction is mediated by the bone resorption activity of 
multinucleated osteoclasts. RANKL is a required activation signal for 
osteoclasts. RANKL is secreted along with other growth factors by 
myeloma plasma B cells.. 
•Activated osteoclasts secrete IL-6 that promotes the survival of myeloma 
plasma B cells 
Pathogenesis  
To improve oxygen and nutrient supply to the myeloma plasma B cells, the 
formation of new blood vessel is promoted by 
soluble factors secreted by both bone marrow stromal cells and myeloma 
plasma B cells. In addition, blood vessel endothelial 
cells also secrete growth factors that promote the survival of the myeloma 
plasma B cells. 
The clinical picture 
Proliferation of plasma  cells 
1. Osteolysis and osteodestruction 
Neurological  disorders  
2. Syndrome of hypercalcemia  
Renal failure 
3.  Inhibition of normal hematopoiesis 
(anemia, pancytopenia) 
1.Hyperviscosity  syndrome 
2.Myeloma nephropathy 
3.Disproteinemia  
Elevated levels of B2-microglobulin   
 Increased levels of IL6 and CRP   
4. Reduction of normal Ig 
Recurrent bacterial infections 
M-protein secretion 
Clinical features of bone disease 
• Bone disease occurs in 80-90% of myeloma 
patients. The development of bone disease, 
either focal or diffuse, can result in pain, 
pathological fractures/spinal cord 
compression and hypercalcaemia  
• Radiotherapy is useful to improve pain control 
and may also promote healing of the fracture 
site. 
Hypercalcaemia 
•Acute hypercalcaemia can present with 
central nervous system dysfunction 
(confusion, coma and obtundation), 
muscle weakness, pancreatitis, 
constipation, thirst, polyuria, shortening of 
the Q-T interval on ECG and acute renal 
insufficiency.  
•All patients with moderate to severe 
hypercalcaemia should receive a 
bisphosphonate. 
http://window.edu.ru/window_catalog/files/r70210/metod_mieloma.pdf 
Hyperviscosity syndrome 
• Hyperviscosity syndrome may develop in patients with high 
serum paraprotein levels, particularly those of IgA and IgG3 
type.  
• Symptoms include blurred vision, headaches, mucosal 
bleeding and dyspnoea due to heart failure.  
• All patients with high protein levels should undergo 
fundoscopy which may demonstrate retinal vein distension, 
haemorrhages and papilloedema.  
• Patients usually have raised plasma viscosity that usually 
corresponds to a serum IgM level of at least 30 g/l, an IgA 
level of 40 g/l and an IgG level of 60 g/l ) 
Renal impairment 
• Renal impairment is a common and 
potentially serious complication of myeloma 
occurring at presentation in 20-25% of 
patients and in up to 50% of patients at some 
time during their disease. 
• Renal failure occurs as a result of damage 
caused to renal tubules by free light chains 
(cast nephropathy, or “myeloma kidney”). A 
variety of other nephrotoxic processes may 
also contribute to this damage including 
dehydration, hypercalcaemia, nephrotoxic 
drugs, and infection 
Myeloma Kidney 
Protein cast 
obstructs tubule 
with syncitial giant 
cell reaction 
around it 
Diagnostic criteria for MGUS, asymptomatic 
myeloma and symptomatic myeloma  
(International Myeloma Working Group, 2003)  
MGUS   Asymptomatic  
myeloma   
 
Symptomatic myeloma 
  
M-protein in serum <30 g/l  M-protein in serum >30 g/l  
and/or  
 
M-protein in serum and/or 
urine**   
Bone marrow clonal 
plasma cells <10 % and low 
level of plasma cell 
infiltration in a trephine 
biopsy (if done)   
Bone marrow clonal 
plasma cells >10 %   
 
Bone marrow (clonal) 
plasma cells or biopsy 
proven plasmacytoma 
  
 
No related organ or tissue 
impairment ((no end organ 
damage including bone 
lesions)   
No related organ or tissue 
impairment (no end organ 
damage including bone 
lesions) or symptoms 
  
 
Myeloma-related organ or 
tissue impairment 
(including bone lesions) 
  
 
Myeloma-related organ or tissue 
impairment (MWG, 2003)  
Clinical effects 
due to myeloma  
Definition   
Increased 
calcium levels  
Corrected serum calcium >0.25mmol/l 
above the upper limit of normal or 
>2.75mmol/l  
Renal 
insufficiency  
Creatinine>173mmol/l   
Anaemia  Haemoglobin 2 g/dl below the lower limit 
of normal or haemoglobin <10 g/dl  
Bone lesions  Lytic lesions or osteoporosis with 
compression fractures  
(MRI or CT may clarify)   
Other   
 
Symptomatic hyperviscosity, amyloidosis, 
recurrent bacterial infections (> 2 episodes 
in 12 months)   
Helpful 
Mnemonic: 
• C - calcium 
• R - renal 
• A-anemia 
• B - bone 
 
International Staging System (ISS) for 
multiple myeloma (adapted from Greipp et al, 2005)  
Stage  
  
Criteria  Median survival in 
  
 
I  
  
Serum ß2 microglobulin < 
3.5 mg/l (296 nmol/l) and 
serum albumin > 3.5 g/dl 
(35g/l or 532 μmol/l)  
62 months   
 
 
II   Neither I or III*  45 months   
III   
 
Serum ß2 microglobulin > 
5.5 mg/l (465 nmol/l)   
29 months   
 
Upper normal value for serum ß2 microglobulin is 2.0 mg/L 
The normal range for serum albumin is 3.5 to 5.5 g/dL 
Imaging techniques in myeloma 
• The skeletal survey should include a postero-anterior (PA) view of the 
chest, antero-posterior (AP) and lateral views of the cervical spine, 
thoracic spine, lumbar spine, humeri and femora, AP and lateral view of 
the skull and AP view of the pelvis; other symptomatic areas should be 
specifically visualized with appropriate views  
• CT scanning or MRI should be used to clarify the significance of ambiguous 
plain radiographic findings such as equivocal lytic lesions, especially in 
parts of the skeleton that are difficult to visualize on plain radiographs, 
such as ribs, sternum and scapulae  
• Urgent MRI is the diagnostic procedure of choice to assess suspected cord 
compression in myeloma patients with or without vertebral collapse  
• Urgent CT scanning is an alternative, when MR imaging is unavailable, 
intolerable or contraindicated 
• CT or MR imaging is indicated to delineate the nature and extent of soft 
tissue masses and where appropriate, tissue biopsy may be guided by CT 
scanning  
 
 

“Punched out” lesions in the bones 
Поражение черепа 
(симптом «перечницы») 
http://www.aic.cuhk.edu.hk/web8/myeloma%20skull.htm 
 http://www.aboutcancer.com/myeloma_images.htm 
Radiography  of the humerus 
http://www.aboutcancer.com/mm_1209_4sah.jp 
CT at the level of the thoracic spine 
http://www.aboutcancer.com/mm_1209_2sah.jpg 
MRI of the thoracic spine 
http://www.aboutcancer.com/myeloma_spine_bmc 
http://trialx.com 
Serum protein electrophoretic 
pattern in multiple myeloma 
The normal plasm protein electrophoretic pattern shows a heavy albumin band (to 
the left) and lighter bands which are alpha, beta and gamma mobility globulins. The 
serum from the patient with multiple myeloma shows a heavy band which is the 
abnormal monoclonal immunoglobulin (referred to as a paraprotein). Because it is 
monoclonal (all molecules identical) it is a very narrow discrete band, which in this 
patient has gamma mobility. 
http://www1.imperial.ac.uk/departmentofmedicine/divisions/experimental
medicine/haematology/morphology/bain/images/slide47/ 
Rouleaux formation 
Excess Ig in the peripheral blood may result in 
Rouleaux formation in which immunoglobulin coated 
RBCs cling together (resembling overlapping pennies). 
The ESR may be increased secondary to hyperviscosity 
Rouleaux 
• Bone marrow aspirate demonstrating plasma 
cells of multiple myeloma. Note the blue 
cytoplasm, eccentric nucleus, and perinuclear 
pale zone (or halo).  
• All images and text are (c) 2002 by the American Society of Hematology. All rights reserved 
Cells containing multiple immunoglobulin globules are 
known as Mott cells 
Treatment options 
• Chemotherapy (Bortezomib, melphalan, thalidomide)  
• Dexamethasone  
• High-dose chemotherapy with transplantation 
• Radiation  
• Alpha-interferon  
• Erythropoietin  
• Bisphosphonates  
• Supporting therapy: antibiotics  Emergency care (eg 
dialysis, plasmapheresis, surgery or radiation), 
pain management, growth 
factors, corsets/fixation,  exercises,  diet. 
Indications for starting therapy  
• Chemotherapy is only indicated in patients with 
symptomatic myeloma based on the presence of ROTI 
• Early intervention in patients with asymptomatic 
myeloma is not required  
• Patients with asymptomatic myeloma should be 
monitored under the supervision of a Consultant 
Haematologist 
• Monitoring of patients with asymptomatic myeloma 
should include regular (typically 3 monthly) clinical 
assessment for the emergence of ROTI and 
measurement of serum and urinary M-protein 
Till we meet again 
